about
Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF.Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxisSildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorGranulocytic myeloid derived suppressor cells expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level.Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein.Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients.Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV.Low plasma concentrations of albumin influence the affinity column-mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation.Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.A rare case of severe myopathy associated with etravirine use.Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir.Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV.Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patients.Altered brain cholesterol/isoprenoid metabolism in a rat model of autism spectrum disorders.UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration.Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAARTMulticompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid deliveryAccumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infectionSildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease InhibitorsWhole blood levels evaluation measuring tacrolimus by ACMIA method on washed erythrocytes in a liver transplant recipient with circulating heterophilic antibodiesDevelopment and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patientsPrevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate TreatmentRandomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment
P50
Q33543869-CFECC37C-67F8-4F77-BF9B-598C2E7FED67Q33850686-2EE54451-C388-44C9-850C-B28B06C0ABF8Q35038647-A371E591-C9CB-4D32-ADB9-B5017064412EQ35290066-468E30D8-37E3-4B0A-B1DB-8E23AFEB241FQ35448784-05A5BCAF-5A52-46BA-BBC5-ACF6C2BAE8EEQ39013665-49F9F157-82B3-45C5-95F7-D6059ECEBAB4Q40152620-0435540A-A652-41D7-B259-313908B3682CQ42261647-BA5C175F-B957-4A7B-B100-90F82719C71BQ42280851-E54C15EB-DD52-45B6-A0F5-4D11430D186AQ42284766-52D92FF8-06A2-4898-8AFB-2AC5B1E800AEQ42663239-9B3E5407-1DAC-451F-8023-66FB9B6CA16DQ43102171-36227BD5-3D70-4ADA-AED9-C25C440E5F6DQ43102175-168B6FDD-CEED-4E50-A0A0-1842D7C2A386Q43189982-660C6C45-4404-4101-A667-4D38DAEE0C2EQ43237659-1F38B84E-D437-4ABD-9CE7-6184EC2D7D3BQ45348395-A4BAD1E4-6815-4421-857D-A0C7983CC902Q46075615-ACD0FCFF-B071-4DD3-8FCF-3FCC7EC61A32Q46111866-927AFB43-3EB1-4E98-83FC-E0B97AAEAB60Q46193537-59E2A0DB-5680-43AA-BA32-F959C776D753Q47197426-FA450BA3-66D0-46D8-ADB8-EEEB3274DC03Q47256204-A2D8AB3A-F527-468A-9B66-15226EE914A9Q49997422-174DAD67-2682-437D-8B74-BBDEA66BDBDAQ50140688-E6E7BF43-E83D-4E1E-A2E9-D20502EDE8D2Q56790172-1F00CBF0-275F-46E9-8053-4452DEB37468Q57235881-30C5E54B-7806-49E9-A316-EF5EEDD49ED6Q57235899-07E2205E-64B8-477C-AA47-FB4302242EB2Q60586181-00DE7A87-D393-47DE-9D35-7C34207E876EQ83806010-9918ADD7-978E-4CEC-A5F1-37808A18FE11Q88567576-E35AE72A-2A03-470B-AA46-5AF7445F97C8Q89179879-AE53F8F3-7394-4F98-B4D8-26F60355DFCDQ91288934-42CC936A-65C6-492D-BF4B-5A9DC603D704
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Massimo Tempestilli
@ast
Massimo Tempestilli
@en
Massimo Tempestilli
@es
Massimo Tempestilli
@nl
type
label
Massimo Tempestilli
@ast
Massimo Tempestilli
@en
Massimo Tempestilli
@es
Massimo Tempestilli
@nl
prefLabel
Massimo Tempestilli
@ast
Massimo Tempestilli
@en
Massimo Tempestilli
@es
Massimo Tempestilli
@nl
P106
P1153
12241968800
P21
P31
P496
0000-0003-3107-7441